ADC Analytical Support

Antibody-drug conjugates (ADCs) are complex therapeutic molecules composed of antibodies, linkers, and cytotoxic payloads, requiring comprehensive analytical strategies to ensure molecular integrity, product consistency, and development success. Protheragen provides integrated ADC analytical and regulatory support services, including analytical method development and validation, structural and quality characterization, and regulatory analytical support. Our services help partners evaluate critical quality attributes (CQAs), establish reliable analytical approaches, and generate essential data to support ADC development and clinical advancement.

ADC Analytical Support Overview

Due to the complexity of ADC molecules, which consist of antibodies, linkers, and cytotoxic payloads, advanced analytical strategies are essential for evaluating critical quality attributes (CQAs), monitoring molecular consistency, and ensuring product quality during development.

Comprehensive ADC analytical characterization involves the assessment of key properties such as molecular identity, purity, conjugation profile, drug-antibody ratio (DAR), structural integrity, impurities, and stability characteristics. These analytical insights support ADC optimization, process understanding, formulation development, and comparability evaluation during different stages of development.

Fig.1 Current focus areas of innovative research in industrial cell line development. (Borbála T, et al., 2020)

Our Services

A comprehensive analytical strategy is critical for ADC development, enabling detailed understanding of molecular characteristics, conjugation performance, product stability, and quality consistency.

Analytical Method Development & Validation

ADC molecules combine biological components and highly potent chemical payloads, requiring specialized analytical methods to accurately evaluate product identity, purity, conjugation characteristics, and stability.

Protheragen develops and validates analytical methods tailored for ADC products, supporting reliable characterization throughout ADC development.

Structure & Quality Characterization

Understanding ADC structure and quality attributes is essential for evaluating product consistency, biological activity, and development potential.

Protheragen provides comprehensive ADC characterization services to analyze molecular structure, conjugation features, impurities, and physicochemical properties.

Stability & Comparability Studies

ADC products require comprehensive stability evaluation due to potential changes in antibody structure, linker stability, payload release, and aggregation behavior.

Protheragen provides stability and comparability studies to evaluate ADC product quality, monitor molecular changes, and support development decisions.

ADC Analytical Stage Support

ADC programs require different analytical strategies at different development stages. From early candidate evaluation to clinical-stage development, comprehensive analytical support helps identify molecular characteristics, monitor product quality, and reduce development risks.

Protheragen provides tailored analytical solutions throughout the ADC development lifecycle, supporting decision-making at each critical milestone.

Development Stage	Analytical Focus
Early Discovery	Candidate characterization and quality attribute evaluation
Process Development	Conjugation monitoring and process optimization support
Formulation Development	Stability assessment and formulation optimization
Clinical Development	Comprehensive characterization and comparability evaluation
Scale-Up & Transfer	Analytical consistency assessment during manufacturing transition

Applications of ADC Analytical Support

Comprehensive analytical characterization plays an essential role in ADC development by providing critical insights into molecular properties, product quality, and development risks. Protheragen supports diverse ADC programs with tailored analytical solutions throughout different development stages.

Early ADC Candidate Characterization

Supporting initial evaluation of ADC molecule properties and development potential.

ADC identity confirmation
Initial structural analysis

Quality attribute evaluation
Candidate selection support

ADC Process Development Support

Providing analytical insights for conjugation and purification optimization.

DAR analysis
Conjugation efficiency assessment

Process parameter evaluation
Product quality monitoring

ADC Formulation Development Support

Evaluating stability characteristics to support formulation optimization.

Stability screening
Aggregation monitoring

Degradation analysis
Formulation comparison

ADC Comparability Assessment

Supporting evaluation of product consistency during development transitions.

Process changes
Scale-up evaluation

Manufacturing transfer support
Candidate comparison

Why Choose Protheragen

Integrated ADC Analytical Capabilities

Combining analytical method development, molecular characterization, and stability evaluation to support ADC programs across development stages.

Comprehensive Understanding of ADC Quality Attributes

Comprehensively evaluating key ADC quality attributes, including DAR, purity, aggregation, molecular integrity, and stability, to support product characterization and development optimization.

Flexible Analytical Strategies

Providing customized analytical solutions based on ADC format, development stage, and project requirements.

Successful ADC development requires a deep understanding of molecular structure, quality attributes, and stability characteristics. Protheragen provides integrated ADC analytical solutions to help partners evaluate, optimize, and advance ADC candidates with confidence. From analytical method development to structural characterization and stability assessment, our expertise supports ADC programs throughout the development lifecycle. Contact us for customized ADC Analytical Support services designed to meet your development needs.

Reference

Borbála T, et al. "Recent advances in CHO cell line development for recombinant protein production" Drug Discovery Today: Technologies, 2020, 38: 25-34.